CN111065412A - Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 - Google Patents
Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 Download PDFInfo
- Publication number
- CN111065412A CN111065412A CN201880059102.7A CN201880059102A CN111065412A CN 111065412 A CN111065412 A CN 111065412A CN 201880059102 A CN201880059102 A CN 201880059102A CN 111065412 A CN111065412 A CN 111065412A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- apatinib
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及PD‑1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途。具体而言,本发明涉及一种抗PD‑1抗体和阿帕替尼联合在制备三阴性乳腺癌的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (14)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017114813580 | 2017-12-29 | ||
CN201711481358 | 2017-12-29 | ||
CN2018110827080 | 2018-09-17 | ||
CN201811082708 | 2018-09-17 | ||
PCT/CN2018/124563 WO2019129168A1 (zh) | 2017-12-29 | 2018-12-28 | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111065412A true CN111065412A (zh) | 2020-04-24 |
CN111065412B CN111065412B (zh) | 2021-10-08 |
Family
ID=67066641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880059102.7A Active CN111065412B (zh) | 2017-12-29 | 2018-12-28 | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210363253A1 (zh) |
EP (1) | EP3733202A4 (zh) |
JP (1) | JP2021508699A (zh) |
KR (1) | KR20200105825A (zh) |
CN (1) | CN111065412B (zh) |
AU (1) | AU2018396889A1 (zh) |
BR (1) | BR112020011796A2 (zh) |
CA (1) | CA3086429A1 (zh) |
MX (1) | MX2020006368A (zh) |
TW (1) | TW201929900A (zh) |
WO (1) | WO2019129168A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202130349A (zh) * | 2019-09-24 | 2021-08-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pd-1抗體聯合紫杉類化合物在製備治療三陰性乳腺癌的藥物中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129252B2 (en) | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
CN101675930B (zh) | 2008-09-16 | 2012-04-25 | 江苏恒瑞医药股份有限公司 | 用于治疗增生性疾病的药物组合物 |
CN101676267B (zh) | 2008-09-16 | 2012-12-26 | 江苏恒瑞医药股份有限公司 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
-
2018
- 2018-12-28 WO PCT/CN2018/124563 patent/WO2019129168A1/zh unknown
- 2018-12-28 EP EP18893813.8A patent/EP3733202A4/en not_active Withdrawn
- 2018-12-28 US US16/956,765 patent/US20210363253A1/en not_active Abandoned
- 2018-12-28 AU AU2018396889A patent/AU2018396889A1/en not_active Abandoned
- 2018-12-28 BR BR112020011796-0A patent/BR112020011796A2/pt not_active IP Right Cessation
- 2018-12-28 JP JP2020535616A patent/JP2021508699A/ja active Pending
- 2018-12-28 CN CN201880059102.7A patent/CN111065412B/zh active Active
- 2018-12-28 MX MX2020006368A patent/MX2020006368A/es unknown
- 2018-12-28 KR KR1020207017977A patent/KR20200105825A/ko not_active Application Discontinuation
- 2018-12-28 TW TW107147760A patent/TW201929900A/zh unknown
- 2018-12-28 CA CA3086429A patent/CA3086429A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
Non-Patent Citations (3)
Title |
---|
ANNAW12502: "PD-1治疗乳腺癌,试出来的惊喜!丨咚友访谈第一期", 《HTTP://WWW.360DOC.COM/CONTENT/17/0210/18/30276536_628086194.SHTM》 * |
DEXIANG YANG等: "Apatinib for heavily treated patients with non-small cell lung cancer:Report of a case series and literature review", 《SAUDI JOURNAL OF BIOLOGICAL SCIENCES》 * |
王晓蕊等: "阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察", 《中国肿瘤临床》 * |
Also Published As
Publication number | Publication date |
---|---|
TW201929900A (zh) | 2019-08-01 |
RU2020123428A3 (zh) | 2022-01-31 |
EP3733202A4 (en) | 2021-10-06 |
CA3086429A1 (en) | 2019-07-04 |
JP2021508699A (ja) | 2021-03-11 |
RU2020123428A (ru) | 2022-01-31 |
EP3733202A1 (en) | 2020-11-04 |
BR112020011796A2 (pt) | 2020-11-17 |
KR20200105825A (ko) | 2020-09-09 |
US20210363253A1 (en) | 2021-11-25 |
WO2019129168A1 (zh) | 2019-07-04 |
CN111065412B (zh) | 2021-10-08 |
AU2018396889A1 (en) | 2020-07-02 |
MX2020006368A (es) | 2020-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 | |
CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
TW201922282A (zh) | Pd-1抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 | |
CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 | |
US9657108B2 (en) | Dosage and administration of anti-EGFR therapeutics | |
CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
CN109793892B (zh) | 一种抗pd-1抗体在制备治疗食管癌的药物中的用途 | |
CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备***的药物中的用途 | |
CN110859959A (zh) | 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途 | |
WO2021057764A1 (zh) | Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途 | |
WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
CN113491769A (zh) | 药物联合 | |
RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы | |
WO2021228978A1 (en) | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies | |
CN111093703A (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备***的药物中的用途 | |
CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备***疾病的药物中的用途 | |
CN110812485A (zh) | 抗pd-1抗体联合化学疗法在制备***的药物中的用途 | |
CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
TW202143969A (zh) | 抗pd-1抗體和多受體酪胺酸激酶抑制劑的藥物組合及其使用方法 | |
WO2019065720A1 (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40025415 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |